Mednax’s (MD) Buy Rating Reiterated at Mizuho
Mednax Inc. (NYSE:MD)‘s stock had its “buy” rating reissued by analysts at Mizuho in a report released on Tuesday. They currently have a $79.00 price target on the stock. Mizuho’s price objective indicates a potential upside of 22.06% from the company’s current price.
A number of other brokerages have also recently commented on MD. Jefferies Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Mednax in a report on Wednesday, June 8th. Zacks Investment Research cut shares of Mednax from a “buy” rating to a “hold” rating in a report on Saturday, July 30th. JPMorgan Chase & Co. cut their target price on shares of Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. Finally, Citigroup Inc. cut their target price on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 17th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $76.11.
Mednax (NYSE:MD) traded up 0.19% during trading on Tuesday, reaching $64.84. 84,563 shares of the company’s stock were exchanged. Mednax has a 52 week low of $61.40 and a 52 week high of $85.10. The firm has a market capitalization of $5.98 billion, a price-to-earnings ratio of 18.10 and a beta of 0.56. The stock has a 50-day moving average price of $65.70 and a 200 day moving average price of $68.21.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/mednaxs-md-buy-rating-reiterated-at-mizuho.html
Mednax (NYSE:MD) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by $0.04. Mednax had a return on equity of 14.88% and a net margin of 11.17%. The company had revenue of $772 million for the quarter, compared to analyst estimates of $775.68 million. During the same period in the previous year, the business posted $0.90 EPS. The firm’s revenue for the quarter was up 14.1% compared to the same quarter last year. Equities research analysts forecast that Mednax will post $4.14 earnings per share for the current fiscal year.
In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $65.01, for a total transaction of $97,515.00. Following the sale, the director now directly owns 12,755 shares in the company, valued at approximately $829,202.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. Profund Advisors LLC raised its stake in shares of Mednax by 0.3% in the second quarter. Profund Advisors LLC now owns 12,470 shares of the company’s stock valued at $903,000 after buying an additional 35 shares during the last quarter. Montag & Caldwell LLC raised its stake in Mednax by 0.5% in the second quarter. Montag & Caldwell LLC now owns 12,900 shares of the company’s stock valued at $934,000 after buying an additional 60 shares in the last quarter. Utah Retirement Systems raised its stake in Mednax by 0.6% in the second quarter. Utah Retirement Systems now owns 16,800 shares of the company’s stock valued at $1,217,000 after buying an additional 100 shares in the last quarter. Mackenzie Financial Corp raised its stake in Mednax by 1.4% in the second quarter. Mackenzie Financial Corp now owns 9,091 shares of the company’s stock valued at $658,000 after buying an additional 123 shares in the last quarter. Finally, Pacer Advisors Inc. raised its stake in Mednax by 9.5% in the second quarter. Pacer Advisors Inc. now owns 1,760 shares of the company’s stock valued at $127,000 after buying an additional 152 shares in the last quarter. Institutional investors own 96.87% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.